tbuckley/cabot-search huggingface dataset:
Congenital Cytomegalovirus Infection
Authors: James B. Hanshaw
Journal: New England Journal of Medicine (1973)

For more than a decade now the Journal has been a prime source of information pertaining to the clinical importance of cytomegalovirus infections. The tacit assumption has been that one day the study of the cytomegaloviruses would move from the backwaters of medical esoterica into the mainstream of clinical medicine. One rising expectation has been that cytomegalovirus would ultimately be shown to be an important cause of Central-nervous-system dysfunction of a variety of types. The paper by Kumar, Nankervis and Gold (p. 1370) must raise questions concerning the validity of this hypothesis. These investigators present evidence that definite neurologic sequelae . . .
Resultados de una investigación paneuropea para valorar la presencia de una nueva variante de Chlamydia trachomatis
Authors: E J Savage, C Ison, M Jw Van de Laar
Journal: Eurosurveillance (2007)

En 2006 se notifico el hallazgo de una nueva variante de Chlamydia trachomatis en Suecia. Hasta ahora son tres los paises — Irlanda, Noruega y Dinamarca — que han detectado esta variante, pero el numero total de casos es muy pequeno.
Inflammatory indexes strongly predict clinical outcome in patients (pts) with metastatic renal cell cancer (mRCC) treated with nivolumab: results from the Italian expanded access program (EAP)
Authors: U. De Giorgi, G. Procopio, A. Guida, A. Bearz, S. Buti, U. Basso, M. Mitterer, C. Ortega, P. Bidoli, F. Ferrau, L. Crinò, A. Frassoldati, P. Marchetti, E. Mini, A. Scoppola, C. Verusio, G. Fornarini, G. Cartenì, C. Caserta, C.N. Sternberg
Journal: Annals of Oncology (2017)
Low-Dose Desmopressin Nasal Spray and FDA Approval
Authors: Seymour Fein, Samuel Herschkowitz
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CNS efficacy results from the phase III ALUR study of alectinib vs chemotherapy in previously treated ALK+ NSCLC
Authors: J. de Castro, S. Novello, J. Mazieres, I.-J. Oh, M.R. Migliorino, A. Helland, R. Dziadziuszko, F. Griesinger, F. de Marinis, A. Zeaiter, A. Cardona, B. Balas, H. Johannsdottir, M. Chlistalla, V. Smoljanovic, J. Wolf
Journal: Annals of Oncology (2017)
Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season
Authors: Marc Rondy, Alin Gherasim, Itziar Casado, Odile Launay, Caterina Rizzo, Daniela Pitigoi, Aukse Mickiene, Sierk D Marbus, Ausenda Machado, Ritva K Syrjänen, Iva Pem-Novose, Judith Krisztina Horváth, Amparo Larrauri, Jesús Castilla, Philippe Vanhems, Valeria Alfonsi, Alina E Ivanciuc, Monika Kuliese, Rianne van Gageldonk-Lafeber, Veronica Gomez, Niina Ikonen, Zvjezdana Lovric, Annamária Ferenczi, Alain Moren
Journal: Eurosurveillance (2017)

In a multicentre European hospital study we measured influenza vaccine effectiveness (IVE) against A(H3N2) in 2016/17. Adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among 65-79-year-olds and 13% (95% CI: -15 to 30) among those ≥ 80 years. As the A(H3N2) vaccine component has not changed for 2017/18, physicians and public health experts should be aware that IVE could be low where A(H3N2) viruses predominate.
Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease
Authors: Jodie Birch, Peter J. Barnes, Joao F. Passos
Journal: Pharmacology & Therapeutics (2017)

Cellular senescence, the irreversible loss of replicative capacity in somatic cells, plays a causal role in the development of age-related pathology and in a number of age-related chronic inflammatory diseases. The ageing lung is marked by an increasing number of senescent cells, and evidence is mounting that senescence may directly contribute to a number of age-related respiratory diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). Telomere dysfunction and alterations in mitochondrial homeostasis frequently occur in cellular senescence and are important to the development of the often detrimental senescence-associated secretory phenotype (SASP). The roles of telomeres, the mitochondria and cellular senescence in lung ageing and disease are discussed. Therapeutic interventions targeting cellular senescence are considered for delaying or potentially reversing age-related respiratory disease.
Comparison of prognostic models for hepatocellular carcinoma (HCC) in patients treated with the sorafenib: Results from a Canadian multi-center HCC database
Authors: H.H. Samawi, S. Hao-Wen, K. Chan, M.A. Alghamdi, R.M. Lee-Ying, J. Knox, P. Gill, A. Romagnino, E. Batuyong, Y-J. Ko, W.Y. Cheung, V.C. Tam
Journal: Annals of Oncology (2017)
The landscape of kinase fusions in 445 Chinese NSCLC patients
Authors: M.W. Chen, H. Chen, M.H. Wang, T. Shou, Y.F. Shi, Q.S. Guo, Y.H. Shang, J. Hu, C. Liu, L. Dai, P. Zhang, G.W. Chirn, K. Wang, M. Yao
Journal: Annals of Oncology (2017)
The role of procollagen alpha 1 type 1 (Col1A1) on invasion and cellular signaling in glioma cells.
Authors: Niramol Savaraj, Shumei Chen, Chunjing Wu, Ying-Ying Li, Medhi Wangpaichitr, Ronald Benveniste, Lynn G. Feun
Journal: Journal of Clinical Oncology (2017)

e23165 Background: We have previously shown that Procollagen alpha 1 type 1 (Col1A1) is found more in low and intermediate grade glioma and less often in glioblastoma(GBM) (Cancer Invest. 23:577, 2005). We now investigate their role in cellular function. Methods: 4 glioma cell lines: Glioma 1 and U118 express high amount of Col1A1 ( Col1A1+) ; A172 and SW1783 express insignificant amount of Col1A1 ( Col1A1 - ) as the model . All four cell lines express SPARC. Scratch, transwell, and metrigel assay were used to study migration and invasion. Cell cycles were analyzed by flowcytometry. Results: U118 has the highest amount of SPARC followed by A172, SW1783 and Glioma 1. Thus it does not appear to have any relationship between these two proteins which are known as binding partner. Glioma 1 showed the least invasion and migration followed by U118, SW1783 and A172. Thus, Col1A1 expression appear to correlate with invasiveness. To further confirm this, we have silence Col1A1 in Glioma 1 and U118 using both siRNA and shRNA. All clones exhibit more migration and invasion. However, it does not affect both intracellular and extracellular levels of SPARC. Silencing Col1A1 results in increasing G2M arrest; 11% in U118 and 6% in Glioma 1. However it does not affect cellular proliferation. To further verify this, we have overexpressed Col1A1 in A172 and SW1783 using plasmid containing Col1A1 and DDK tag. These Col1A1 (+) A172 and SW1783 transfectants exhibit less migration and invasion. However, there is no effect on SPARC levels. These Col1A1 positive cells exhibit 12% increase in Go/G1 arrest and decrease in proliferation. A limited protein array also showed that silencing Col1A1 increase in STAT3, 5 and 6 and AKT levels. Interestingly, a difference in sensitivity to STAT3/5 inhibitors also noted in parental and their Col1A1 knock down transfectants. Conclusions: our results support the role of Col1A1 in glioma cell invasiveness, and hence confirm our previous data which showed that Col1A1 is found more in low grade and intermediate grade glioma. Thus, Col1A1 could be an additional useful marker to assess the aggressiveness of GBM beside histopathological grading. Col1A1 may also play a role in cellular signaling pathway.
Tumor-penetrating peptide iRGD conjugation effectively potentiates intratumor T cell infiltration.
Authors: Naiqing Ding, Shu Su, Fanyan Meng, Huizi Sha, Fangjun Chen, Jia Wei, Hong Chen, Shiyao Du, Baorui Liu
Journal: Journal of Clinical Oncology (2017)

e14543 Background: Poor infiltration of activated lymphocytes into solid tumors can be a fundamental factor limiting their efficacy. The purpose of this study was to determine whether a cycled tumor-penetrating peptide, iRGD, with a well-defined role in delivering drugs into extravascular tumor tissues, could facilitate lymphocytes infiltration into tumors in both the iRGD combination regimen and conjugated pattern. Methods: We used polyethylene glycol-conjugated phospholipid (PEG-lipid) derivatives, a time-efficient and versatile platform, to immobilize iRGD on T cell membrane, and examined the ability of iRGD to improve lymphocytes infiltration into tumors in multicellular spheroids and two xenograft mouse models. Furthermore, the synergy effect of iRGD modification and PD-1 gene knock out in adoptive T cell transfer immunotherapy was evaluated in a xenograft model of EBV associated gastric cancer. Results: In this study, we first showed that systematic injection of iRGD could double the number of CD3 + T cells in 4T1 tumor in BALB/C mouse and the synthetic iRGD-PEG-lipid, which could spontaneously transfer from solution to cell surfaces, had no effect to cell vitality, proliferation, phenotype and function. In adoptive transfer studies, the infiltration of T cells could be promoted by the co-administration with iRGD while T cells modified with iRGD could spread more extensively throughout both the multicellular spheroids and tumor mass. Furthermore, We demonstrated that iRGD modified T cells had superior antitumor efficiency to iRGD combination regimen due to increased T cell infiltration, and exhibited robust synergy effect with PD-1 gene knock out. Conclusions: Our study offers a simple method to target immune cells into tumors and may have the potential to enhance the clinical efficacy of adoptive T cell immunotherapy.
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia
Authors: Bernd Boidol, Christoph Kornauth, Emiel van der Kouwe, Nicole Prutsch, Lukas Kazianka, Sinan Gültekin, Gregor Hoermann, Marius E. Mayerhoefer, Georg Hopfinger, Alexander Hauswirth, Michael Panny, Marie-Bernadette Aretin, Bernadette Hilgarth, Wolfgang R. Sperr, Peter Valent, Ingrid Simonitsch-Klupp, Richard Moriggl, Olaf Merkel, Lukas Kenner, Ulrich Jäger, Stefan Kubicek, Philipp B. Staber
Journal: Blood (2017)
NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications
Authors: Antonio Russo, Giacomo Oliveira, Sofia Berglund, Raffaella Greco, Valentina Gambacorta, Nicoletta Cieri, Cristina Toffalori, Laura Zito, Francesca Lorentino, Simona Piemontese, Mara Morelli, Fabio Giglio, Andrea Assanelli, Maria Teresa Lupo Stanghellini, Chiara Bonini, Jacopo Peccatori, Fabio Ciceri, Leo Luznik, Luca Vago
Journal: Blood (2017)
Deviations From Clinical Trials Registration in the ED-SAFE Study—Reply
Authors: Ivan W. Miller, Carlos A. Camargo, Edwin D. Boudreaux
Journal: JAMA Psychiatry (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Legionnaires´ disease clusters associated with travel to Spain during the period January 2001 to July 2003
Authors: R Cano, N Prieto, C Martin, C Pelaz, S Mateo
Journal: Eurosurveillance (2004)

Epidemiological surveillance and control of travel associated cases of legionnaires' disease are necessary tasks for public health and collaboration between countries is necessary to do this. Within the framework of the European Surveillance Scheme for Travel Associated Legionnaires' Disease (EWGLINET), European Guidelines for Control and Prevention of Travel Associated Legionnaires' Disease have been produced . This has established the reporting and response criteria when cases or clusters appear. In this paper the analysis of the information corresponding to the 46 reported clusters related to Spain is presented. Data corresponds to the period January 2001 to July 2003.
Relato de um caso de difteria adquirido em laboratório
Authors: H. K. Geiss, W Kiehl, W Thilo
Journal: Eurosurveillance (1997)

Em Marco 1996, quando uma tecnica de laboratorio, de 41 anos de idade apareceu doente, com febre moderada, dor de garganta, rouquidao e disfagia, foi submetida, inicialmente, a um tratamento sintomatico. Um dia mais tarde, a doente foi observada na sala de urgencia de uma clinica de otorrinolaringologia com sinais de dispneia, grande edema da faringe, membrana esbranquicada estendendo-se para alem da amigdala direita sobre palato mole, adenopatia e edema cervical. Uma provavel difteria foi entao diagnosticada. Uma traqueotomia foi imediatamente executada.
Strategy and technology to prevent hospital-acquired infections: Lessons from SARS, Ebola, and MERS in Asia and West Africa
Authors: Sanjeewa Jayachandra Rajakaruna, Wen-Bin Liu, Yi-Bo Ding, Guang-Wen Cao
Journal: Military Medical Research (2017)

Hospital-acquired infections (HAIs) are serious problems for healthcare systems, especially in developing countries where public health infrastructure and technology for infection preventions remain undeveloped. Here, we characterized how strategy and technology could be mobilized to improve the effectiveness of infection prevention and control in hospitals during the outbreaks of Ebola, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) in Asia and West Africa. Published literature on the hospital-borne outbreaks of SARS, Ebola, and MERS in Asia and West Africa was comprehensively reviewed. The results showed that healthcare systems and hospital management in affected healthcare facilities had poor strategies and inadequate technologies and human resources for the prevention and control of HAIs, which led to increased morbidity, mortality, and unnecessary costs. We recommend that governments worldwide enforce disaster risk management, even when no outbreaks are imminent. Quarantine and ventilation functions should be taken into consideration in architectural design of hospitals and healthcare facilities. We also recommend that health authorities invest in training healthcare workers for disease outbreak response, as their preparedness is essential to reducing disaster risk.
Puerto Rico’s morgues full of uncounted bodies as hurricane death toll continues to rise
Authors: Owen Dyer
Journal: BMJ (2017)

Only a small fraction of the people who have died in Puerto Rico as a result of Hurricane Maria, which struck the island on 20 September, have been included in official statistics, reports indicate.

The category 4 storm forced 51 of the island’s 69 hospitals temporarily to close their doors to new patients. Sixty four hospitals are now at least partly operating, though only 17 have grid power and the rest are using generators. The 1000 bed US navy hospital ship Comfort arrived in San Juan harbour on 4 October to help with the relief effort.

With roads closed and phone services down, however, transfer and triage of patients at the most overcrowded emergency rooms is a major challenge. “We can’t communicate with anybody,” said Carlos Gomez Marcial, emergency medical director …
Dialysate Potassium, Dialysate Magnesium, and Hemodialysis Risk
Authors: Patrick H. Pun, John P. Middleton
Journal: Journal of the American Society of Nephrology (2017)

One of the fundamental goals of the hemodialysis prescription is to maintain serum potassium levels within a narrow normal range during both the intradialytic and interdialytic intervals. Considering the extraordinarily high rate of cardiovascular mortality in the hemodialysis population, clinicians are obligated to explore whether factors related to dialytic potassium removal can be modified to improve clinical outcomes. Observational studies and circumstantial evidence suggest that extreme concentrations of serum and dialysate potassium can trigger cardiac arrest. In this review, we provide an overview of factors affecting overall potassium balance and factors modulating potassium dialysate fluxes in dialysis, and we review data linking serum and dialysate potassium concentrations with arrhythmias, cardiovascular events, and mortality. We explore potential interactions between serum and dialysate magnesium levels and risks associated with dialysate potassium levels. Finally, we conclude with proposed dialytic and novel nondialytic approaches to optimize outcomes related to potassium homeostasis in patients on hemodialysis. Dialysis clinicians need to consider changes in the overall clinical scenario when choosing dialysate potassium concentrations, and an effective change in practice will require more frequent serum potassium monitoring and responsive dialysis care teams.
ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)
Authors: J. Ledermann, A.M. Oza, D. Lorusso, C. Aghajanian, A. Oaknin, A. Dean, N. Colombo, J. Weberpals, A. Clamp, G. Scambia, A. Leary, R. Holloway, D.M. O'Malley, T. Cameron, L. Maloney, S. Goble, K.K. Lin, J. Sun, H. Giordano, R. Coleman
Journal: Annals of Oncology (2017)
BEACON CRC: safety lead-in (SLI) for the combination of binimetinib (BINI), encorafenib (ENCO), and cetuximab (CTX) in patients (pts) with BRAF-V600E metastatic colorectal cancer (mCRC)
Authors: S. Huijberts, J.H.M. Schellens, E. Elez, P-J. Cuyle, E. Van Cutsem, R. Yaeger, M. Fakih, C. Montagut, M. Peeters, J. Desai, T. Yoshino, F. Ciardiello, H. Wasan, A. Grothey, K. Maharry, A. Gollerkeri, S. Kopetz
Journal: Annals of Oncology (2017)
Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era.
Authors: Chetasi Talati, Leidy Lismeri Isenalumhe, Samantha Reiter Shams, Andrew Tucker Kuykendall, Julio C. Chavez, Bijal D. Shah, Kendra Lynn Sweet, Javier Pinilla-Ibarz
Journal: Journal of Clinical Oncology (2017)

e18546 Background: Primary goal in management of chronic myeloid leukemia (CML) is to prevent progression to BP-CML. Even with the use of induction chemotherapy with a TKI, outcome remains dismal in BP-CML. We describe our experience with the management of BP-CML. Methods: Retrospective chart review was performed on CML patients treated between 2001 and 2016. Out of 585 CML cases, 58 (10%) had a diagnosis of BP-CML. Kaplan-Meier method with log-rank test was utilized for survival calculations. All p-values calculated were two sided. Results: The overall survival (OS) of BP-CML cohort was 31.9 months (mo) from diagnosis. In the patients diagnosed in chronic or accelerated phase, median time to progression to BP-CML was 19.1 mo. The median OS from the BP-CML diagnosis was not different when progressed from an earlier phase compared toBP-CML (10.8 vs 11.0, p 0.62). Trend toward worse OS was noted in myeloid BP-CML compared to lymphoid BP-CML (9.2 vs 17.5 mo, p 0.32). The median OS in the single agent TKI cohort (n=21) was 12.8 mo vs 10.9 mo (p 0.72) in the combination cohort (n = 36). Treatment with a single agent TKI vs combination therapy did not significantly impact OS in either myeloid (9.2 vs 9.1 mo, p 0.32) or lymphoid (14.5 vs 18.3 mo, p 0.24) BP-CML. Out of 26 patients (44.8%) who received allogeneic stem cell transplant, 26% (n=6) received a single agent TKI prior to transplant and 76.9% (n=20) received combination therapy. A trend toward improved OS was noted in the single agent TKI cohort (128.5 vs 24.0 mo, p 0.23). When stratified by the presence of standard Philadelphia chromosome or with additional cytogenetic aberrations, no difference in OS was noted (10.9 vs 12.1 mo, p 0.51). Monosomy 7 was present in greater frequency in lymphoid BP-CML than myeloid BP-CML (35.7% vs 6.3%, p 0.02). Conclusions: Our data suggest no survival difference when BP-CML is treated with a single agent TKI compared to a combination therapy, regardless of histology type. Therefore, single agent TKIs should be considered as an effective frontline therapy option for BP-CML, which may prevent the potential toxicity associated with chemotherapy. These findings need further validation in a larger prospective cohort.
Correlation between overall survival (OS) and time to progression (TTP) and between OS and response rate (RR) by RECIST in advanced hepatocellular carcinoma (HCC)
Authors: L. Huang, Y. De Sanctis, M. Shan, J. Bruix, J.M. Llovet, A-L. Cheng, G. Meinhardt, K. Nakajima
Journal: Annals of Oncology (2017)
Preparing for the Next Harvey, Irma, or Maria — Addressing Research Gaps
Authors: James M. Shultz, Sandro Galea
Journal: New England Journal of Medicine (2017)

Extreme events often cast in bold relief what we do and don’t know about medicine and public health. In recent weeks, Hurricanes Harvey, Irma, and Maria have illuminated our knowledge gaps regarding the consequences of disasters and their mitigation.
Preliminary report of an autochthonous chikungunya outbreak in France, July to September 2017
Authors: Clémentine Calba, Mathilde Guerbois-Galla, Florian Franke, Charles Jeannin, Michelle Auzet-Caillaud, Gilda Grard, Lucette Pigaglio, Anne Decoppet, Joel Weicherding, Marie-Christine Savaill, Manuel Munoz-Riviero, Pascal Chaud, Bernard Cadiou, Lauriane Ramalli, Pierre Fournier, Harold Noël, Xavier De Lamballerie, Marie-Claire Paty, Isabelle Leparc-Goffart
Journal: Eurosurveillance (2017)

In August 2017, an autochthonous chikungunya case was reported in south-east France. By mid-September, eight additional autochthonous cases were found in the index case's neighbourhood, where the chikungunya virus vector Aedes albopictus was observed. Genomic characterisation identified an East-Central South African (ECSA) lineage strain, probably from the Central African region and carrying an adaptive mutation facilitating transmission by Ae. albopictus. The event confirms we need early case detection and response to contain chikungunya in Europe.